All Type of News
‘Botox’ and ‘Filler’ leading the local clinic market
It was a year with unusually fierce competition between Botox and Filler. The reason why the year was attracting was because domestic products have occupied the local clinic market over products of competitive multina...
MOHW decides to invest KRW 457 billion into R&D in 2016
The Ministry of Health and Welfare(MOHW) has decided to invest KRW 457 billion in the R&D business of the next year.
The MOHW(Minister Jin-yup Jung) held the Health and Medical Service Technology Deliberation Committ...
SK Chemicals announces the world’s first commercialization approval of tetravalent cell-cultured influenza vaccineOn the 24th, SK Chemicals(CEO Man-hoon Park) announced acquisition of commercialization approval of ‘SKYCellflu Quadrivalent,’ a tetravalent cell-cultured influence vaccine, fro...
|
Takeda left by CEO Choon-yup Lee appoints a new foreigner in the new yearThe CEO position of Takeda Pharmaceuticals Korea, which has been vacant since the resignation of CEO Choon-yup Lee, will be filled next year.
The headquarters of Takeda Pharmac...
|
Approval of Abilify Inj makes confrontation against Janssen’s Invega
In the long-acting injectable(LAI) market for schizophrenia, which has been monopolized by Janssen with Invega Sustenna Inj, Korea Otsuka Pharmaceuticals’ Abilify Inj formed the 2-way competition as acquiring approval...
Oral antirheumatic ‘Xeljanz’ settles the Big 4 hospitals in 9 months
Pfizer Pharmaceuticals Korea’s ‘Xeljanz(generic name: tofacitinib),’ an oral rheumatoid arthritis treatment, has been safely landed in the Big 4 hospitals within 9 months of the launch on March.
According to the medi...
High-handed behaviors of multinational pharmaceutical company raise complaints in the distribution industry
The multinational pharmaceutical companies’ high-handed business behaviors have raised complaints of employees working in distribution companies.
They show much nicer business behaviors towards medical institutions, ...
Daiichi Sankyo Korea and Daewoong announce co-promotion agreement of ‘Lixiana’Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21st.
Daiich...
|
Hanmi Pharm reveals negotiation techniques with ‘big pharmas’Hanmi Pharm will unveil know-hows of negotiations for the large-hit new drug license agreements this year, and widely open doors to R&D for domestic biotechnology ventures havin...
|
SK Chemical-developed hemophilia treatment applied for EMA approvalA hemophilia treatment, developed by the SK Chemicals’ own technology, is about to target the foreign advanced markets.
On the 23rd, SK Chemicals(CEO Man-hoon Park) announced C...
|
